Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
West Virginia University
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Goethe University
M.D. Anderson Cancer Center
The First Affiliated Hospital of Soochow University
St. Jude Children's Research Hospital
University of Maryland, Baltimore
Massachusetts General Hospital
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center
First Affiliated Hospital of Zhejiang University
The First Affiliated Hospital of Soochow University
Stichting Hemato-Oncologie voor Volwassenen Nederland
The First Affiliated Hospital of Soochow University
First Affiliated Hospital of Zhejiang University
Institute of Hematology and Blood Transfusion, Czech Republic
The First Affiliated Hospital of Soochow University
Ludwig-Maximilians - University of Munich
St. Anna Kinderkrebsforschung
Sichuan University
Sichuan University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
The First Affiliated Hospital of Soochow University
Duke University
University of British Columbia
Israeli Medical Association
Assistance Publique - Hôpitaux de Paris
Gruppo Italiano Malattie EMatologiche dell'Adulto